Authors
Loading...
Preclinical study demonstrates that selective LAT1 inhibitor KYT-0353 suppresses colon cancer growth in vitro and in vivo, indicating its potential as an anti-tumor agent.
Oda et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: